New muscular dystrophy drug's chances for approval improve

New muscular dystrophy drug's chances for approval improve
A new drug to treat Duchenne muscular dystrophy may be closer to becoming the first approved treatment for the disease.

(HealthDay)—A new drug to treat Duchenne muscular dystrophy may be closer to becoming the first approved treatment for the disease.

Eteplirsen was created to treat Duchenne muscular dystrophy, which affects about one in 3,500 boys worldwide. The drug seemed to be on track for swift approval from the U.S. Food and Drug Administration, but that effort stalled late last year after a similar type of for the disease failed in a clinical trial, the Washington Post reported.

However, Massachusetts-based Sarepta Therapeutics said Monday that FDA officials outlined a potential way forward for the drug and said they may consider it for accelerated approval.

"This provides the opportunity to get the drug approved and in the hands of all the boys who can benefit from it sometime in 2015," Sarepta chief executive officer Chris Garabedian told the Post.

add to favorites email to friend print save as pdf

Related Stories

Treating Duchenne muscular dystrophy

Dec 02, 2013

(Medical Xpress)—Reviving a gene which is 'turned down' after birth could be the key to treating Duchenne muscular dystrophy (DMD), an incurable muscle-wasting condition that affects one in every 3,500 ...

New breakthrough could help treat muscular dystrophy

Aug 13, 2012

A researcher in the Faculty of Medicine & Dentistry at the University of Alberta improved Duchenne muscular dystrophy symptoms in non-human lab models, using a new drug cocktail. The drug combination targets ...

Recommended for you

Powdered measles vaccine found safe in early clinical trials

10 hours ago

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

Health care M&A leads global deal surge

Nov 23, 2014

In a big year for deal making, the health care industry is a standout. Large drugmakers are buying and selling businesses to control costs and deploy surplus cash. A rising stock market, tax strategies and ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.